Oncology

DenseWolf-K, a hybrid AI framework, achieved 99.64% accuracy in brain tumour MRI classification, revolutionising medical imaging.

Nivolumab shows lasting melanoma recurrence prevention, with long-term safety, in largest-ever CheckMate 238 trial analysis.

A new study has identified TRIM56, an E3 ubiquitin ligase, as a key activator of the proto-oncogene Src in hepatocellular carcinoma.

A new study has found that it is older age hat is most strongly linked to poorer survival outcomes in liver cancer.

Sacituzumab tirumotecan improves survival over platinum chemotherapy in EGFR‑mutated NSCLC, OptiTROP‑Lung04 finds.

Early clinical results reveal that the novel KRAS G12D inhibitor GFH375 achieves a 41% response rate and 97% disease control in advanced…

The DESTINY-Breast11 phase 3 trial presented at ESMO 2025 revealed that the anthracycline-free neoadjuvant T-DXd-THP regimen achieved a 67.3% pathologic complete response rate.

A risk-stratified approach significantly enhanced skin cancer detection after organ transplantation without increasing health care burden.